Latest Period
Q1 2026
Security Snapshot
Denali Therapeutics Inc. - COMMON STOCK (DNLI) Institutional Ownership
CUSIP: 24823R105
13F Institutional Holders and Ownership History from Q4 2017 to Q1 2026
Institutions Reporting
266
Shares (Excl. Options)
147,410,490
Price
$19.20
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- DNLI on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 147,410,490
- Total 13F value
- $2,821,046,986
- Portfolio coverage rank
- 0.01%
- Share change
- -3,802,038
- Value change
- -$42,869,658
- Number of holders
- 266
- Shares outstanding
- 157,762,815
- SEC-reported price per share
- $19.71
- Insider filing price
- $19.71
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- DNLI - Denali Therapeutics Inc. - COMMON STOCK is tracked under CUSIP 24823R105.
- 266 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 248 to 266 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $2,495,633,592 to $2,821,046,986.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 266 institutions filings for Q1 2026.
Security key
24823R105
Latest holder period
Q1 2026
13F holders
266
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
DNLI full holder history
Denali Therapeutics Inc. SEC filings
Denali Therapeutics Inc. company facts
Denali Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 24823R105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
DNLI
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 7.2% | $173,095,065 | 10,490,610 | BlackRock, Inc. | 31 Mar 2025 | |||
| T. Rowe Price Investment Management, Inc. | 5.4% | $163,568,486 | 8,519,192 | T. Rowe Price Investment Management, Inc. | 31 Mar 2026 | |||
| FMR LLC | 4.2% | -27% | $128,121,587 | -$35,777,146 | 6,672,999 | -22% | FMR LLC | 31 Mar 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.9% | $82,251,923 | 5,664,733 | Wellington Management Group LLP | 30 Jun 2025 | |||
| Capital Research Global Investors | 3.8% | $90,373,982 | 5,477,211 | Capital Research Global Investors | 31 Dec 2024 | |||
| BAILLIE GIFFORD & CO | 5.6% | -23% | $31,927,897 | -$7,858,384 | 2,198,891 | -20% | BAILLIE GIFFORD & CO | 30 Jun 2025 |
As of 31 Mar 2026, 266 institutional investors reported holding 147,410,490 shares of Denali Therapeutics Inc. - COMMON STOCK (DNLI). This represents 93% of the company’s total 157,762,815 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
70%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.3% | 13,034,434 | +2.5% | 0% | $250,261,131 |
| BAILLIE GIFFORD & CO | 7.6% | 12,066,479 | -2% | 0.24% | $231,676,397 |
| T. Rowe Price Investment Management, Inc. | 5.4% | 8,519,192 | +17% | 0.11% | $163,569,000 |
| Temasek Holdings (Private) Ltd | 4.4% | 7,012,974 | 0% | 0.45% | $134,649,101 |
| STATE STREET CORP | 4% | 6,272,001 | +0.14% | 0% | $120,422,419 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 6,147,957 | 0% | 0% | $118,040,774 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.9% | 6,120,160 | 0% | 0.01% | $117,507,072 |
| FMR LLC | 2.9% | 4,575,374 | -25% | 0% | $87,847,187 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2.8% | 4,432,314 | -11% | 0.02% | $85,100,430 |
| GOLDMAN SACHS GROUP INC | 2.8% | 4,407,255 | +15% | 0.01% | $84,619,301 |
| BAKER BROS. ADVISORS LP | 2.4% | 3,731,695 | 0% | 0.41% | $71,648,544 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 3,727,114 | +7.8% | 0% | $71,575,052 |
| Holocene Advisors, LP | 2% | 3,195,429 | +1.4% | 0.15% | $61,352,237 |
| ALLIANCEBERNSTEIN L.P. | 1.8% | 2,893,618 | -19% | 0.02% | $47,773,633 |
| DIMENSIONAL FUND ADVISORS LP | 1.7% | 2,692,175 | +13% | 0.01% | $51,686,812 |
| UBS Group AG | 1.6% | 2,571,344 | +6.9% | 0.01% | $49,369,805 |
| Pictet Asset Management Holding SA | 1.6% | 2,558,865 | +93% | 0.05% | $48,439,203 |
| Capital Research Global Investors | 1.6% | 2,514,588 | -33% | 0.01% | $48,280,090 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.6% | 2,464,146 | -37% | 0.01% | $47,313,000 |
| Fisher Asset Management, LLC | 1.5% | 2,436,895 | -5.9% | 0.02% | $46,788,383 |
| Crestline Management, L.P. | 1.4% | 2,210,732 | -21% | 92% | $42,446,054 |
| Alyeska Investment Group, L.P. | 1.2% | 1,941,123 | +126% | 0.11% | $37,269,562 |
| Lynx1 Capital Management LP | 1.2% | 1,880,303 | +8.1% | 5.7% | $36,101,818 |
| ADAR1 Capital Management, LLC | 1.2% | 1,871,455 | +3491% | 2.2% | $35,931,936 |
| Aberdeen Group plc | 1.2% | 1,854,446 | -8.8% | 0.06% | $35,605,363 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
34
Latest
Q1 2026
Rows shown
1-25 of 34
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 147,410,490 | $2,821,046,986 | -$42,869,658 | $19.20 | 266 |
| 2025 Q4 | 151,143,703 | $2,495,633,592 | +$260,890,342 | $16.51 | 248 |
| 2025 Q3 | 135,496,675 | $1,967,413,218 | -$29,612,796 | $14.52 | 236 |
| 2025 Q2 | 137,594,175 | $1,925,023,022 | +$63,128,608 | $13.99 | 228 |
| 2025 Q1 | 132,874,634 | $1,807,534,753 | +$50,388,875 | $13.60 | 219 |
| 2024 Q4 | 127,929,251 | $2,607,162,085 | +$11,750,487 | $20.38 | 222 |
| 2024 Q3 | 126,754,706 | $3,691,746,017 | +$83,332,107 | $29.13 | 215 |
| 2024 Q2 | 123,900,320 | $2,876,933,310 | +$81,781,105 | $23.22 | 202 |
| 2024 Q1 | 122,410,671 | $2,512,114,129 | +$149,691,318 | $20.52 | 208 |
| 2023 Q4 | 115,037,875 | $2,465,293,115 | +$48,272,802 | $21.46 | 208 |
| 2023 Q3 | 108,753,813 | $2,243,639,062 | +$15,314,130 | $20.63 | 194 |
| 2023 Q2 | 107,385,972 | $3,168,950,262 | +$5,897,175 | $29.51 | 198 |
| 2023 Q1 | 108,017,472 | $2,487,976,875 | +$45,585,839 | $23.04 | 198 |
| 2022 Q4 | 106,059,670 | $2,949,511,974 | +$353,989,026 | $27.81 | 195 |
| 2022 Q3 | 92,590,614 | $2,841,171,715 | -$31,157,203 | $30.69 | 192 |
| 2022 Q2 | 92,689,565 | $2,727,755,557 | +$180,988,868 | $29.43 | 177 |
| 2022 Q1 | 86,720,578 | $2,790,606,045 | +$40,452,227 | $32.17 | 177 |
| 2021 Q4 | 85,268,721 | $3,803,185,901 | +$18,535,233 | $44.60 | 204 |
| 2021 Q3 | 82,102,816 | $4,142,844,228 | +$169,589,833 | $50.45 | 205 |
| 2021 Q2 | 77,780,665 | $6,099,806,785 | +$34,022,640 | $78.44 | 204 |
| 2021 Q1 | 77,751,278 | $4,438,997,286 | +$78,721,718 | $57.10 | 213 |
| 2020 Q4 | 66,445,136 | $5,564,771,315 | +$193,800,989 | $83.76 | 199 |
| 2020 Q3 | 82,769,611 | $2,965,793,194 | +$14,445,549 | $35.83 | 168 |
| 2020 Q2 | 82,768,394 | $2,001,309,869 | +$63,425,607 | $24.18 | 142 |
| 2020 Q1 | 80,458,775 | $1,408,929,438 | +$149,773,734 | $17.51 | 127 |